Alefacept, a fusion protein approved for psoriasis, has been Walled in patients with new-onset type 1 diabetes mellitus. However, the withdrawal of the drug from the US market and the unmet primary end point do not raise hope for this drug, even though some secondary end points were met and the study highlighted interesting immunological efficacy.
Diabetes: Immunotherapy for T1DM--still not there yet / Buzzetti, Raffaella. - In: NATURE REVIEWS. ENDOCRINOLOGY. - ISSN 1759-5029. - STAMPA. - 9:12(2013), pp. 697-698. [10.1038/nrendo.2013.221]
Diabetes: Immunotherapy for T1DM--still not there yet.
BUZZETTI, Raffaella
2013
Abstract
Alefacept, a fusion protein approved for psoriasis, has been Walled in patients with new-onset type 1 diabetes mellitus. However, the withdrawal of the drug from the US market and the unmet primary end point do not raise hope for this drug, even though some secondary end points were met and the study highlighted interesting immunological efficacy.File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
